These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 22495193

  • 1. Minimal change (steroid sensitive) nephrotic syndrome in children: new aspects on pathogenesis and treatment.
    Oh J, Kemper MJ.
    Minerva Pediatr; 2012 Apr; 64(2):197-204. PubMed ID: 22495193
    [Abstract] [Full Text] [Related]

  • 2. [Minimal change nephrotic syndrome : new insights into disease pathogenesis].
    Audard V, Lang P, Sahali D.
    Med Sci (Paris); 2008 Oct; 24(10):853-8. PubMed ID: 18950582
    [Abstract] [Full Text] [Related]

  • 3. Direct Effects of Immunomodulatory Agents on Podocytes in Immune-Mediated Glomerular Diseases.
    Manabe S, Nitta K, Nagata M.
    Contrib Nephrol; 2018 Oct; 195():131-142. PubMed ID: 29734158
    [Abstract] [Full Text] [Related]

  • 4. Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy.
    Yang T, Nast CC, Vo A, Jordan SC.
    Nephrol Dial Transplant; 2008 Jan; 23(1):377-80. PubMed ID: 17981884
    [No Abstract] [Full Text] [Related]

  • 5. The treatment of relapse in adults with minimal change nephrotic syndrome: myths and facts.
    Shigidi MM.
    Saudi J Kidney Dis Transpl; 2011 Jan; 22(1):10-7. PubMed ID: 21196608
    [Abstract] [Full Text] [Related]

  • 6. Childhood nephrotic syndrome--current and future therapies.
    Greenbaum LA, Benndorf R, Smoyer WE.
    Nat Rev Nephrol; 2012 Jun 12; 8(8):445-58. PubMed ID: 22688744
    [Abstract] [Full Text] [Related]

  • 7. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis.
    Kronbichler A, Bruchfeld A.
    Nephron Clin Pract; 2014 Jun 12; 128(3-4):277-82. PubMed ID: 25401966
    [Abstract] [Full Text] [Related]

  • 8. Evaluation and management of steroid-sensitive nephrotic syndrome.
    Hodson EM, Alexander SI.
    Curr Opin Pediatr; 2008 Apr 12; 20(2):145-50. PubMed ID: 18332709
    [Abstract] [Full Text] [Related]

  • 9. The podocyte as a direct target of immunosuppressive agents.
    Schönenberger E, Ehrich JH, Haller H, Schiffer M.
    Nephrol Dial Transplant; 2011 Jan 12; 26(1):18-24. PubMed ID: 20937691
    [Abstract] [Full Text] [Related]

  • 10. Treatment of focal segmental glomerulosclerosis.
    Meyrier A.
    Expert Opin Pharmacother; 2005 Aug 12; 6(9):1539-49. PubMed ID: 16086641
    [Abstract] [Full Text] [Related]

  • 11. Tacrolimus treatment for steroid- and cyclosporin-resistant minimal-change nephrotic syndrome.
    Schweda F, Liebl R, Riegger GA, Krämer BK.
    Nephrol Dial Transplant; 1997 Nov 12; 12(11):2433-5. PubMed ID: 9394341
    [No Abstract] [Full Text] [Related]

  • 12. Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome.
    Eguchi A, Takei T, Yoshida T, Tsuchiya K, Nitta K.
    Nephrol Dial Transplant; 2010 Jan 12; 25(1):124-9. PubMed ID: 19740915
    [Abstract] [Full Text] [Related]

  • 13. [Tacrolimus: secondary or main player in children with steroid-resistant nephrotic syndrome?].
    Semeraro L.
    G Ital Nefrol; 2012 Jan 12; 29(6):649. PubMed ID: 23229661
    [No Abstract] [Full Text] [Related]

  • 14. Management of childhood onset nephrotic syndrome.
    Gipson DS, Massengill SF, Yao L, Nagaraj S, Smoyer WE, Mahan JD, Wigfall D, Miles P, Powell L, Lin JJ, Trachtman H, Greenbaum LA.
    Pediatrics; 2009 Aug 12; 124(2):747-57. PubMed ID: 19651590
    [Abstract] [Full Text] [Related]

  • 15. [Minimal Change Glomerulonephritis].
    Stracke S, Helmchen U, Aymanns C, Kadlec N, Lindemann B, Hüttner S, Keller F.
    Internist (Berl); 2003 Sep 12; 44(9):1090-7. PubMed ID: 14566462
    [Abstract] [Full Text] [Related]

  • 16. [Advances in the treatment of adult nephrotic syndrome].
    Yokoyama H, Asaka M, Yamaya H, Wada T.
    Nihon Jinzo Gakkai Shi; 2007 Sep 12; 49(2):108-12. PubMed ID: 17375618
    [No Abstract] [Full Text] [Related]

  • 17. The efficacy of cyclosporine A in adult nephrotic syndrome with minimal change disease and focal-segmental glomerulosclerosis: a multicenter study in Korea.
    Lee HY, Kim HS, Kang CM, Kim SG, Kim MJ.
    Clin Nephrol; 1995 Jun 12; 43(6):375-81. PubMed ID: 7554521
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial.
    Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A.
    Am J Kidney Dis; 2009 May 12; 53(5):760-9. PubMed ID: 19268410
    [Abstract] [Full Text] [Related]

  • 19. Use of tacrolimus in steroid- and cyclophosphamide-resistant minimal change nephrotic syndrome.
    Tang S, Tang AW, Tam MK, Ho YW.
    Am J Kidney Dis; 2003 Nov 12; 42(5):E13-5. PubMed ID: 14582073
    [Abstract] [Full Text] [Related]

  • 20. The role of B7-1 in proteinuria of glomerular origin.
    Novelli R, Benigni A, Remuzzi G.
    Nat Rev Nephrol; 2018 Sep 12; 14(9):589-596. PubMed ID: 29959373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.